Boussard & Gavaudan Investment Management’s Zura Bio ZURA Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio ZURA Stock Details ZURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-375,000	Closed	-$3.83M	–	136
2022 Q4	$3.83M	Hold	375,000	–	–	0.42%	58
2022 Q3	$3.77K	Hold	375,000	–	–	0.53%	49
2022 Q2	$3.73K	Buy	+375,000	New	+$3.73M	0.68%	42
2022 Q1	–	Sell	-375,000	Closed	-$3.69M	–	79
2021 Q4	$3.69M	Hold	375,000	–	–	0.32%	58
2021 Q3	$3.68K	Buy	+375,000	New	+$3.68M	0.31%	54

Other funds holding ZURA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAMU

SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Boussard & Gavaudan Investment Management's ZURA Position: Q1 2023 in Review

Boussard & Gavaudan Investment Management sold out of Zura Bio (ZURA) in Q1 2023, closing a stake of 375,000 shares — an estimated $3.83M sold.

Boussard & Gavaudan Investment Management first reported a position in ZURA in Q3 2021 and held it in 5 quarters. The position peaked at $3.83M in Q4 2022. 3 funds tracked by Wall St. Rank hold ZURA as of Q1 2023.

Boussard & Gavaudan Investment Management reported no remaining Zura Bio position as of Q1 2023 after selling out during the quarter.
Boussard & Gavaudan Investment Management sold 375,000 Zura Bio shares in Q1 2023, an estimated $3.83M.
Boussard & Gavaudan Investment Management first reported a position in Zura Bio in Q3 2021 and held it in 5 quarters.
Boussard & Gavaudan Investment Management's Zura Bio position peaked at $3.83M in Q4 2022.
3 funds tracked by Wall St. Rank held Zura Bio as of Q1 2023.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q1 2023, filed 11 May 2023.